NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
Children's Oncology Group
Pediatric Brain Tumor Consortium
Children's Oncology Group
Australasian Gastro-Intestinal Trials Group
Australasian Gastro-Intestinal Trials Group